(Adds shares in paragraph 2, details on disease in paragraph 3 and 4, background in paragraphs 5-7)
Sept 19 (Reuters) - The U.S. Food and Drug Administration has declined to approve Vanda Pharmaceuticals'
drug to treat stomach paralysis symptoms, the company said on Thursday.
Shares of the company fell about 14% to $4.26 in premarket trading.
Vanda was seeking the health regulator's nod for the drug tradipitant to treat gastroparesis, a condition characterized by delayed gastric emptying.
The disease is associated with symptoms such as severe nausea, vomiting, and difficulty finishing a normal meal.
Vanda licensed tradipitant from Eli Lilly and is also studying it for motion sickness.
The health regulator had imposed a partial clinical hold on tradipitant, preventing trials longer than 12 weeks.
The company plans to submit a separate application for the drug to prevent vomiting in motion sickness later this year.
(Reporting by Sriparna Roy in Bengaluru; Editing by Abinaya Vijayaraghavan)
((Sriparna.Roy@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。